Has Eric Schneider, MD received payments from drug or device companies?

Yes. Drug and device makers reported $134,159 in general payments to Eric Schneider, MD across 169 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Eric Schneider, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Eric Schneider, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Eric Schneider, MD

Retina Specialist · Nashville, TNNPI 1790949485

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $90,959 of the $134,159 with a category attached, or 67.8%. 19 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 47.2% of the total. Reporting peaked in 2024 at $46,774 and has fallen 73.3% since, to $12,472 in 2025. Among retina specialist clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$134,159in general payments, 2019–2025

Across 169 payments — averaging $793.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Carl Zeiss Meditec, Inc.$63K
Regeneron$27K
US Retina LLC$18K
Regeneron Healthcare Solutions, Inc.$14K
Carl Zeiss Meditec USA, Inc.$9K
Genentech USA, Inc.$963
plus $3K from 13 others

$3,900,911in research payments, 2019–2025

Across 1,943 payments — averaging $2007.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Regeneron$2.9M
Boehringer Ingelheim$708K
Boehringer Ingelheim International GmbH$288K
Astellas Pharma Global Development$14K
Hoffmann-la Roche Limited$11K

What the payments were for

Consulting fees$90,95968%
Speaking & faculty fees$19,35014%
Travel & lodging$2,3982%
Food & beverage$4,6463%
Education$420%
Ownership interest$7,2625%
Other$9,5027%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Carl Zeiss Meditec, Inc.	26	$63,382
Regeneron	25	$26,526
US Retina LLC	8	$17,564
Regeneron Healthcare Solutions, Inc.	27	$13,820
Carl Zeiss Meditec USA, Inc.	6	$8,787
Genentech USA, Inc.	24	$963
Boehringer Ingelheim International GmbH	1	$950
Apellis Pharmaceuticals, Inc.	15	$475
Genentech, Inc.	5	$399
Astellas Pharma US Inc	6	$232
Ocular Therapeutix, Inc.	2	$212
AbbVie(2 entities)	10	$211
Cardinal Health 110 LLC	1	$150
Alimera Sciences, Inc.	6	$137
Neurotech Pharmaceuticals, Inc.	1	$125
Bausch & Lomb, A Division Of Bausch Health US, LLC	1	$118
Biogen	3	$73
Eyepoint US, Inc.	1	$19
Amgen	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$134,159 in reported general payments places this provider in the 90th percentile of 58 retina specialist providers in Tennessee.

See all retina specialist providers in Tennessee →

Medicare billing

Part B allowed, 2024

$5,491,790

Medicare patients

1,188

Services billed

42,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	149	$6,529
Bromfenac Sodium	19	$4,344
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	84	$1,158
Latanoprost	113	$1,031
Ciprofloxacin Hcl	71	$914
Ketorolac Tromethamine	31	$804
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	57	$752
Tobramycin-DexamethasoneTobramycin/Dexamethasone	11	$577
Timolol Maleate	29	$193
Brimonidine Tartrate	21	$180
ErythromycinErythromycin Base	12	$150

Paid to pharmacies, not to this prescriber.

Other retina specialist in Nashville

Carl AwhNashville$1.3M
Peter SonkinNashville$949K
Brandon BusbeeNashville$566K
David ReichsteinNashville$114K
Akshay ThomasNashville$108K
Franco RecchiaNashville$72K
Everton ArrindellNashville$39K
Roy WallaceNashville$19K
Kenneth MoffatNashville$17K
Brigid MarshallNashville$5K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →